The Influence of Coronavirus Disease-2019 (COVID-19) On Parkinson's Disease: An Updated Systematic Review.
ACE2
COVID-19
Parkinson’s disease
SARS-CoV-2
neurological
Journal
Journal of primary care & community health
ISSN: 2150-1327
Titre abrégé: J Prim Care Community Health
Pays: United States
ID NLM: 101518419
Informations de publication
Date de publication:
Historique:
entrez:
18
8
2021
pubmed:
19
8
2021
medline:
24
8
2021
Statut:
ppublish
Résumé
COVID-19 has affected global communities with multiple neurological complications in addition to other critical medical issues. COVID-19 binds to the host's angiotensin-converting enzyme 2 (ACE2) receptors, which are expressed in the neurons and glial cells, acting as an entry port to the central nervous system (CNS). ACE2 receptors are abundantly expressed on dopamine neurons, which may worsen the prognosis of motor symptoms in Parkinson's disease (PD). SARS-CoV-2 may lead to an indirect response via immune-mediated cytokine storms and propagate through the CNS leading to damage. In this systematic review, we aim to provide thorough analyses of associations between COVID-19 and neurological outcomes for patients with PD. Using PRISMA statement 2020, a systematic review was conducted to isolate confirmed COVID-19 patients and analyze the PD-associated neurological outcomes using the following databases: PubMed, Science Direct, Google Scholar, and Cochrane databases. The following keywords were used "COVID19, SARS-CoV-2, Parkinson's disease, Pandemic, Mortality." A modified Delphi process was employed. Of the 355 studies located during the initial round of screening, 16 were included in the final synthesis. Of PD patients who tested positive for SARS-CoV-2, worsening motor symptoms and other viral-associated symptoms were reported. These symptoms included bradykinesia, tremors, gait disturbances, delirium and dementia, and severe spasms of arms and legs. Encephalopathy was presented in 2 of the included studies. Increased mortality rates were identified for hospitalized patients due to COVID-19 and PD as compared to other patient groups. Patients with PD may experience substantial worsening of symptoms due to COVID 19. Given the novelty of neurological-viral associations, clinical studies in the future ought to explore the disease severity and neurological outcomes in COVID-19 positive patients with PD as compared to non-PD patients, in addition to understanding the role of ACE2 in increased vulnerability to contracting the infection and as a treatment modality.
Sections du résumé
BACKGROUND
COVID-19 has affected global communities with multiple neurological complications in addition to other critical medical issues. COVID-19 binds to the host's angiotensin-converting enzyme 2 (ACE2) receptors, which are expressed in the neurons and glial cells, acting as an entry port to the central nervous system (CNS). ACE2 receptors are abundantly expressed on dopamine neurons, which may worsen the prognosis of motor symptoms in Parkinson's disease (PD). SARS-CoV-2 may lead to an indirect response via immune-mediated cytokine storms and propagate through the CNS leading to damage. In this systematic review, we aim to provide thorough analyses of associations between COVID-19 and neurological outcomes for patients with PD.
METHODS
Using PRISMA statement 2020, a systematic review was conducted to isolate confirmed COVID-19 patients and analyze the PD-associated neurological outcomes using the following databases: PubMed, Science Direct, Google Scholar, and Cochrane databases. The following keywords were used "COVID19, SARS-CoV-2, Parkinson's disease, Pandemic, Mortality." A modified Delphi process was employed.
RESULTS
Of the 355 studies located during the initial round of screening, 16 were included in the final synthesis. Of PD patients who tested positive for SARS-CoV-2, worsening motor symptoms and other viral-associated symptoms were reported. These symptoms included bradykinesia, tremors, gait disturbances, delirium and dementia, and severe spasms of arms and legs. Encephalopathy was presented in 2 of the included studies. Increased mortality rates were identified for hospitalized patients due to COVID-19 and PD as compared to other patient groups.
CONCLUSION
Patients with PD may experience substantial worsening of symptoms due to COVID 19. Given the novelty of neurological-viral associations, clinical studies in the future ought to explore the disease severity and neurological outcomes in COVID-19 positive patients with PD as compared to non-PD patients, in addition to understanding the role of ACE2 in increased vulnerability to contracting the infection and as a treatment modality.
Identifiants
pubmed: 34404266
doi: 10.1177/21501327211039709
pmc: PMC8377313
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
21501327211039709Références
J Med Virol. 2020 Jun;92(6):552-555
pubmed: 32104915
Radiology. 2020 Aug;296(2):E119-E120
pubmed: 32228363
Mov Disord. 2021 Jan;36(1):1-10
pubmed: 33196119
Clin Park Relat Disord. 2021;4:100082
pubmed: 33263105
J Parkinsons Dis. 2020;10(2):351-354
pubmed: 32250324
Ther Adv Chronic Dis. 2020 Aug 11;11:2040622320949423
pubmed: 32850107
Neurology. 2020 Aug 4;95(5):195-196
pubmed: 32487714
Rev Neurol (Paris). 2021 Jan-Feb;177(1-2):134-136
pubmed: 32951860
N Engl J Med. 2020 Jun 25;382(26):2574-2576
pubmed: 32302082
Parkinsonism Relat Disord. 2021 Jun;87:155-161
pubmed: 33931304
HeartRhythm Case Rep. 2020 May 05;6(7):363-366
pubmed: 32373465
Int J Surg. 2021 Apr;88:105906
pubmed: 33789826
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
Brain Behav Immun. 2020 Jul;87:93-94
pubmed: 32335192
Cell Mol Neurobiol. 2020 Aug 25;:
pubmed: 32840758
Mov Disord. 2020 Jun;35(6):912-914
pubmed: 32304118
J Parkinsons Dis. 2021;11(2):431-444
pubmed: 33492244
Mov Disord. 2020 Jun;35(6):905-908
pubmed: 32347572
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Parkinsons Dis. 2020;10(4):1365-1377
pubmed: 32925107
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):889-891
pubmed: 32354768
Cureus. 2020 Mar 21;12(3):e7352
pubmed: 32328364
Geriatrics (Basel). 2020 Sep 18;5(3):
pubmed: 32962001
J Neurol. 2021 Apr;268(4):1179-1187
pubmed: 32880722
Mov Disord. 2020 Aug;35(8):1295-1296
pubmed: 32583481
J Chin Med Assoc. 2020 Mar;83(3):217-220
pubmed: 32134861
Turk J Emerg Med. 2021 Feb 12;21(2):43-50
pubmed: 33969238
Parkinsons Dis. 2020 Oct 5;2020:1216568
pubmed: 33062247
Autoimmun Rev. 2020 May;19(5):102523
pubmed: 32205186
Lancet Psychiatry. 2020 Jul;7(7):611-627
pubmed: 32437679
Neurology. 2020 Aug 11;95(6):e767-e772
pubmed: 32439821
Mov Disord Clin Pract. 2020 Apr 16;7(4):355-356
pubmed: 32373650
Int J Infect Dis. 2020 May;94:55-58
pubmed: 32251791
Acta Neurochir (Wien). 2020 Jul;162(7):1491-1494
pubmed: 32367205
J Neurol. 2021 Aug;268(8):2666-2670
pubmed: 33098468
J Neural Transm (Vienna). 2021 Jan;128(1):37-48
pubmed: 33392827
Mov Disord. 2020 Aug;35(8):1287-1292
pubmed: 32449528
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
Parkinsonism Relat Disord. 2020 Sep;78:134-137
pubmed: 32827969
J Mov Disord. 2020 May;13(2):105-114
pubmed: 32344993
Mov Disord. 2020 Oct;35(10):1712-1716
pubmed: 32776601
Postgrad Med J. 2020 Dec;96(1142):753-758
pubmed: 32563999
Mov Disord Clin Pract. 2020 Apr 16;7(4):357-360
pubmed: 32373651
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Parkinsonism Relat Disord. 2020 Nov;80:7-9
pubmed: 32920322